Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrimethamine for Relapsed/Refractory MDS
NCT03057990Phase 1Withdrawn
- Sponsor
- Montefiore Medical Center
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyrimethamine in myelodysplastic syndrome (MDS), sponsored by Montefiore Medical Center. Primary endpoints: Dose-limiting toxicity at Day 28, Maximum tolerated dose up to 28 days and 1 more. Planned start Sep 2019; status: withdrawn.
02
Drugs
pyrimethamine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03057990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057990.